NASDAQ:VTYX Ventyx Biosciences (VTYX) Stock Price, News & Analysis $3.18 -0.02 (-0.63%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$3.16 -0.02 (-0.50%) As of 04:12 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Ventyx Biosciences Stock (NASDAQ:VTYX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Ventyx Biosciences alerts:Sign Up Key Stats Today's Range$3.13▼$3.2150-Day Range$1.45▼$3.2752-Week Range$0.78▼$3.39Volume469,942 shsAverage Volume1.22 million shsMarket Capitalization$226.29 millionP/E RatioN/ADividend YieldN/APrice Target$10.00Consensus RatingModerate Buy Company Overview Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California. Read More Ventyx Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks72nd Percentile Overall ScoreVTYX MarketRank™: Ventyx Biosciences scored higher than 72% of companies evaluated by MarketBeat, and ranked 320th out of 936 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingVentyx Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageVentyx Biosciences has received no research coverage in the past 90 days.Read more about Ventyx Biosciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Ventyx Biosciences are expected to decrease in the coming year, from ($2.09) to ($2.11) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ventyx Biosciences is -1.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ventyx Biosciences is -1.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVentyx Biosciences has a P/B Ratio of 0.89. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Ventyx Biosciences' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.01% of the float of Ventyx Biosciences has been sold short.Short Interest Ratio / Days to CoverVentyx Biosciences has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Ventyx Biosciences has recently decreased by 99.89%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVentyx Biosciences does not currently pay a dividend.Dividend GrowthVentyx Biosciences does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.01% of the float of Ventyx Biosciences has been sold short.Short Interest Ratio / Days to CoverVentyx Biosciences has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Ventyx Biosciences has recently decreased by 99.89%, indicating that investor sentiment is improving significantly. News and Social Media3.6 / 5News Sentiment1.42 News SentimentVentyx Biosciences has a news sentiment score of 1.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.09 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Ventyx Biosciences this week, compared to 2 articles on an average week.Search Interest6 people have searched for VTYX on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.MarketBeat Follows2 people have added Ventyx Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Ventyx Biosciences insiders have not sold or bought any company stock.Percentage Held by Insiders18.18% of the stock of Ventyx Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions97.88% of the stock of Ventyx Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Ventyx Biosciences' insider trading history. Receive VTYX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ventyx Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address VTYX Stock News HeadlinesIs Ventyx Biosciences (NASDAQ:VTYX) In A Good Position To Invest In Growth?July 22, 2025 | uk.finance.yahoo.comVentyx Biosciences (VTYX) Upgraded to Strong Buy: What Does It ... - NasdaqJuly 11, 2025 | nasdaq.com$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could be the biggest technology story of this decade. In short, he believes what he's holding in his hand is the key to the $100 trillion AI boom… And only one company here in the U.S. can mine this obscure metal. | Brownstone Research (Ad)Analysts Are Bullish on Top Healthcare Stocks: Eli Lilly & Co (LLY), Ventyx Biosciences (VTYX)June 24, 2025 | theglobeandmail.comVTYX - Ventyx Biosciences Inc News - MorningstarJune 24, 2025 | morningstar.comMVTYX - Ventyx Biosciences Inc Financials - MorningstarJune 24, 2025 | morningstar.comMVentyx Biosciences Insiders Placed Bullish Bets Worth US$1.26mJune 17, 2025 | finance.yahoo.comVentyx Biosciences' Study of VTX3232 Met Safety, Tolerability ObjectivesJune 17, 2025 | marketwatch.comSee More Headlines VTYX Stock Analysis - Frequently Asked Questions How have VTYX shares performed this year? Ventyx Biosciences' stock was trading at $2.19 at the beginning of the year. Since then, VTYX stock has increased by 45.2% and is now trading at $3.18. How were Ventyx Biosciences' earnings last quarter? Ventyx Biosciences, Inc. (NASDAQ:VTYX) issued its earnings results on Thursday, May, 8th. The company reported ($0.39) EPS for the quarter, beating analysts' consensus estimates of ($0.48) by $0.09. When did Ventyx Biosciences IPO? Ventyx Biosciences (VTYX) raised $152 million in an IPO on Thursday, October 21st 2021. The company issued 9,472,656 shares at $15.00-$17.00 per share. Who are Ventyx Biosciences' major shareholders? Ventyx Biosciences' top institutional investors include CWM LLC (0.08%), Vanguard Personalized Indexing Management LLC (0.07%), Wealth Enhancement Advisory Services LLC (0.04%) and Pallas Capital Advisors LLC (0.03%). Insiders that own company stock include Somu Subramaniam, Nsv Partners Iii Lp, Raju Mohan, John Nuss, Christopher W Krueger, Sheila Gujrathi, William J Sandborn and Martin Auster. View institutional ownership trends. How do I buy shares of Ventyx Biosciences? Shares of VTYX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Ventyx Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Ventyx Biosciences investors own include Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), SPDR S&P 500 ETF Trust (SPY), JPMorgan Chase & Co. (JPM) and Netflix (NFLX). Company Calendar Last Earnings5/08/2025Today7/28/2025Next Earnings (Estimated)8/14/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:VTYX CIK1851194 Webwww.ventyxbio.com Phone760-593-4832FaxN/AEmployees30Year FoundedN/APrice Target and Rating Average Price Target for Ventyx Biosciences$10.00 High Price Target$14.00 Low Price Target$6.00 Potential Upside/Downside+214.5%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($1.75) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$135.12 million Net MarginsN/A Pretax MarginN/A Return on Equity-47.45% Return on Assets-43.49% Debt Debt-to-Equity RatioN/A Current Ratio19.57 Quick Ratio19.57 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.59 per share Price / Book0.89Miscellaneous Outstanding Shares71,160,000Free Float58,224,000Market Cap$226.29 million OptionableOptionable Beta0.93 Social Links Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report This page (NASDAQ:VTYX) was last updated on 7/28/2025 by MarketBeat.com Staff From Our PartnersAI Frenzy Could Send ‘EarnPhone’ SoaringThe hidden fuel behind AI? Your phone. Billions of data points — from your clicks, swipes, scrolls, and sea...Mode Mobile | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredAI's Next Magnificent SevenThe original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredA grave, grave error.Nvidia just hit $4 trillion… but a tech apocalypse may already be underway. A controversial new documentary...Porter & Company | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ventyx Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ventyx Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.